Article ; Online: Disease-modifying genetic factors in cystic fibrosis.
Current opinion in pulmonary medicine
2018 Volume 24, Issue 3, Page(s) 296–308
Abstract: Purpose of review: To compile data from the past 10 years regarding the role of modifying genes in cystic fibrosis (CF).: Recent findings: CF is a model disease for understanding of the action of modifying genes. Although it is a monogenic (CFTR) ... ...
Abstract | Purpose of review: To compile data from the past 10 years regarding the role of modifying genes in cystic fibrosis (CF). Recent findings: CF is a model disease for understanding of the action of modifying genes. Although it is a monogenic (CFTR) autosomal recessive disease, CF presents with wide phenotypic variability. In CF, variability occurs with different intensity among patients by each organ, being organ-specific, resulting from the mutual interaction of environmental and genetic factors, including CFTR mutations and various other genes, most of which are associated with inflammatory processes. In individuals, using precision medicine, gene modification studies have revealed individualized responses to drugs depending on particular CFTR mutations and modifying genes, most of which are alternative ion channels. Summary: Studies of modifying genes in CF allow: understanding of clinical variability among patients with the same CFTR genotype; evaluation of precision medicine; understanding of environmental and genetic effects at the organ level; understanding the involvement of genetic variants in inflammatory responses; improvements in genetic counseling; understanding the involvement of genetic variants in inflammatory responses in lung diseases, such as asthma; and understanding the individuality of the person with the disease. |
---|---|
MeSH term(s) | Cystic Fibrosis/complications ; Cystic Fibrosis/drug therapy ; Cystic Fibrosis/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/genetics ; Exocrine Pancreatic Insufficiency/complications ; Exocrine Pancreatic Insufficiency/genetics ; Genetic Therapy ; Genotype ; Humans ; Meconium Ileus/complications ; Meconium Ileus/genetics ; Mutation ; Osteoporosis/complications ; Osteoporosis/genetics ; Precision Medicine |
Chemical Substances | Cystic Fibrosis Transmembrane Conductance Regulator (126880-72-6) |
Language | English |
Publishing date | 2018-03-08 |
Publishing country | United States |
Document type | Journal Article ; Research Support, Non-U.S. Gov't ; Review |
ZDB-ID | 1285505-4 |
ISSN | 1531-6971 ; 1070-5287 ; 1078-1641 |
ISSN (online) | 1531-6971 |
ISSN | 1070-5287 ; 1078-1641 |
DOI | 10.1097/MCP.0000000000000479 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 4900: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.